Social services
Exclusive Patent License for Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy
The National Cancer Institute has announced its intention to grant an exclusive patent license to practice inventions related to engineered tumor-infiltrating lymphocytes for cancer therapy to Iovance Biotherapeutics, Inc. This license would allow Iovance to develop, manufacture, distribute, sell, and use autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy products for